Figure 3.

Kaplan-Meier curves illustrating the temporal relationship between selected AEIs and zanubrutinib exposure for (A) common AEIs (neutropenia, infection, and all-grade hemorrhage) and (B) less common or rare events (second primary malignancies [predominantly skin cancers], hypertension, atrial fibrillation/flutter, opportunistic infection, and major hemorrhage). Major hemorrhage is defined as any grade ≥3 or serious hemorrhage or any central nervous hemorrhage of any grade. The y-axis is the cumulative proportion of patients reporting a first event over the duration of study treatment (x-axis).